Short Interest in Rallybio Corporation (NASDAQ:RLYB) Expands By 21.5%

Rallybio Corporation (NASDAQ:RLYB) was the recipient of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 141,643 shares, an increase of 21.5% from the January 15th total of 116,605 shares. Currently, 3.0% of the shares of the company are short sold. Based on an average daily volume of 169,162 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 169,162 shares, the days-to-cover ratio is currently 0.8 days. Currently, 3.0% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RLYB. Renaissance Technologies LLC boosted its holdings in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares in the last quarter. Finally, Susquehanna International Group LLP grew its holdings in Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after acquiring an additional 113,031 shares during the period. 90.34% of the stock is currently owned by institutional investors and hedge funds.

Rallybio Trading Up 1.0%

Shares of RLYB stock opened at $4.82 on Tuesday. The company has a market capitalization of $25.45 million, a P/E ratio of -1.88 and a beta of -1.05. The business’s 50 day moving average is $5.45 and its two-hundred day moving average is $4.99. Rallybio has a twelve month low of $1.76 and a twelve month high of $6.75.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rallybio presently has a consensus rating of “Reduce” and an average price target of $40.00.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.